[Comment] Aiming for complete responses in renal-cell carcinoma

Treatments for metastatic renal-cell carcinoma have evolved rapidly in the past decade, and since 2006, targeted therapies have been the cornerstone of treatments, with pazopanib or sunitinib leading to objective responses in 24 –31% of patients.1 Deep tumour responses have been described as a surrogate measure for overall survival in patients with renal-cell carcinoma.2 However, because these are rarely achieved with current standard first-line targeted therapies, novel tyrosine-kinase inhibitors (TKIs) are being tested.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Comment Source Type: research